Financial
FY2025 revenue SEK 1.34bn (+12.8%); operating margin 21.7%; net income SEK 228.0m.
Balance sheet figures not captured from release.
RaySearch Laboratories
HQ Sweden · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: RAY-B.ST
FY2025 revenue SEK 1.34bn (+12.8%); operating margin 21.7%; net income SEK 228.0m.
Balance sheet figures not captured from release.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | SEK 1.3bn | +12.8% | SEK 292m | SEK 228m | RaySearch Laboratories |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Jul 2026: RaySearch issued a profit warning for Q2 2026, citing several postponed US deals; net sales fell to SEK 272m from SEK 305m. The CEO said the deals were delayed rather than lost.
Cyber & information governance
No data breaches, cyber incidents or regulator actions involving RaySearch Laboratories found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Nov 2025: RaySearch initiated an FDA Class 2 recall of RayStation/RayPlan 2024B (v16.0.0) because calculated dose was not correctly invalidated for certain regions of interest; users were given a workaround and a fix was planned for the next version.
Contract performance
Feb 2026: RaySearch announced that The Royal Marsden NHS Foundation Trust is using RayStation for online adaptive radiotherapy on conventional linacs; in Aug 2026 it reported a RayStation order from the University of North Carolina School of Medicine.
Competitors
No competitors linked yet.